Samsung Epis Unit Submits US FDA Application for Keytruda Biosimilar

MT Newswires Live11-03

Samsung Bioepis, a subsidiary of Samsung Epis (KRX:0126Z0), submitted a biologics license application to the U.S. FDA on Thursday, Oct. 29, for SB27, a biosimilar of Merck's Keytruda, or pembrolizumab, according to a Korea filing on Monday.

The biologics license application takes into account 18 cancer indications, including melanoma, lung cancer, and breast cancer, the filing said.

The submission comes after a Phase Three trial involving 555 patients with metastatic non-squamous non-small cell lung cancer, which demonstrated equivalent efficacy and comparable safety between SB27 and Keytruda, it said.

Shares of Samsung Epis fell over 1% in recent trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment